Related Experiment Video
Updated: Apr 1, 2026
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
6.2K
CD73: A potential biomarker for anti-PD-1 therapy
Paul A Beavis1, Clare Y Slaney1, Nicole Milenkovski1
1Cancer Immunology Program; Peter MacCallum Cancer Centre ; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Clayton, Australia.
Oncoimmunology
|October 10, 2015
Summary
Tumor CD73 expression hinders anti-PD-1 therapy effectiveness. Combining anti-PD-1 with A2A blockade can overcome this limitation, offering a promising cancer treatment strategy.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- CD73 is frequently overexpressed in various human cancers.
- Anti-PD-1 immunotherapy is a key cancer treatment, but its efficacy is often limited.
- Adenosine A2A receptor (A2A) antagonists have been investigated for other conditions.
Purpose of the Study:
- To investigate the role of tumoral CD73 expression in limiting anti-PD-1 therapy efficacy.
- To evaluate the potential of combining anti-PD-1 therapy with A2A blockade to overcome CD73-mediated resistance.
Main Methods:
- The study likely involved preclinical models or analysis of patient data to assess CD73 expression.
- Experimental therapies involving anti-PD-1 and A2A antagonists were administered.
- Tumor response and immune cell activity were measured.
Main Results:
- Tumoral CD73 expression was found to significantly limit the efficacy of anti-PD-1 therapy.
- Concomitant blockade of the A2A receptor rescued the anti-tumor activity of anti-PD-1 therapy.
- This combination strategy demonstrated improved therapeutic outcomes in the study models.
Conclusions:
- Tumoral CD73 is a critical factor limiting anti-PD-1 therapy response.
- Combining anti-PD-1 therapy with A2A blockade presents a viable strategy to enhance cancer immunotherapy.
- This combination warrants further clinical investigation for cancer patients.
